Abstract: Objective To study the effects of tigecycline on coagulation function of patients.Methods The clinical data on 74 inpatients who used tigecycline at Beijing Tongren Hospital between January 1, 2017 and December 31, 2019 was collected. The levels of fibrinogen (FIB), prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time(TT), international normalized ratio(INR), and levels of D-dimer, platelets (PLT), alanine aminotransferase (ALT), total bilirubin(Tbil) and creatinine (CREA) before, during and after medication were recorded to assess the effect of tigecycline on coagulation function. Results The FIB level was significantly decreased while the median levels of aPTT, PT, TT and INR were all significantly increased (P<0.05). Spearman correlation coefficients revealed a strong positive association between the extent to which FIB declined and the baseline level of this parameter(R²=0.726,P<0.001). The FIB level returned to the pre-treatment level at day 6 after discontinuation, so did the levels of aPTT, PT, TT and INR at day 2 after discontinuation. There was no statistically significant difference in levels of ALT, Tbil, CREA and PLT before or after medication (P>0.05).Conclusion Tigecycline can prolong PT, aPTT, TT, INR and reduce the level of FIB. The decline of FIB is the key to abnormal coagulation function among patients who use tigecycline. The coagulation function should be closely monitored when the drug is used.

Key words: tigecycline, coagulation dysfunction, fibrinogen